Cargando…
Reduced Immunogenicity of Intraparenchymal Delivery of Adeno-Associated Virus Serotype 2 Vectors: Brief Overview
Pre existing immunity to adeno-associated virus (AAV) poses a concern in AAV vector–mediated gene therapy. Localized administration of low doses of carefully chosen AAV serotypes can mitigate the risk of an immune response. This article will illustrate the low risk of immune response to AAV serotype...
Autores principales: | Hwu, Wuh-Liang, Muramatsu, Shin-ichi, Gidoni-Ben-Zeev, Bruria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178513/ https://www.ncbi.nlm.nih.gov/pubmed/34551695 http://dx.doi.org/10.2174/1566523221666210922155413 |
Ejemplares similares
-
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
por: Pourshafie, Naemeh, et al.
Publicado: (2018) -
Axonal transport of adeno-associated viral vectors is serotype-dependent
por: Salegio, Ernesto A., et al.
Publicado: (2012) -
Targeted Gene Delivery into the Mammalian Inner Ear Using Synthetic Serotypes of Adeno-Associated Virus Vectors
por: Kim, Min-A, et al.
Publicado: (2019) -
Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse
por: Schuster, Daniel J., et al.
Publicado: (2014) -
Adeno-Associated Viral Vectors Serotype 8 for Cell-Specific Delivery of Therapeutic Genes in the Central Nervous System
por: Pignataro, Diego, et al.
Publicado: (2017)